Bone marrow transplant trial for patients 12 to 80
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This trial provides bone marrow for transplant to patients who are already considered good candidates for a donor transplant by their own doctor. The goal is to see if using this bone marrow product is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 80 years old.
- Your doctor has decided you are eligible for a bone marrow transplant from a donor.
- Your doctor believes the potential benefits of the transplant outweigh the risks for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies stem cell transplants from donors that are fully or partially matched to patients with blood cancers. It compares a new stem cell product from Ossium Health with standard donor transplants to see how well they work.
This trial tests whether transplanting cells from a child's own bone marrow, combined with rehabilitation therapy, can improve movement and function in young children with cerebral palsy caused by birth-related brain injury or bleeding. The goal is to see if this approach helps children move better and become more independent.
This study collects blood samples from patients with aplastic anemia, sickle cell disease, thalassemia, or other bone marrow failure conditions who are receiving a stem cell transplant or gene therapy. The samples will be stored and used for future research to better understand and treat these diseases.
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
This early-stage study tests a specific chemotherapy “conditioning” regimen to prepare the body for a bone marrow transplant in children with certain non-cancer blood or immune conditions. It may help the transplant work better, but it also carries risks from the chemotherapy and transplant process.
Hear when a new Bone Marrow Transplant (BMT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.